Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathway and network analysis of more than 2500 whole cancer genomes.
Reyna MA, Haan D, Paczkowska M, Verbeke LPC, Vazquez M, Kahraman A, Pulido-Tamayo S, Barenboim J, Wadi L, Dhingra P, Shrestha R, Getz G, Lawrence MS, Pedersen JS, Rubin MA, Wheeler DA, Brunak S, Izarzugaza JMG, Khurana E, Marchal K, von Mering C, Sahinalp SC, Valencia A; PCAWG Drivers and Functional Interpretation Working Group; Reimand J, Stuart JM, Raphael BJ; PCAWG Consortium. Reyna MA, et al. Nat Commun. 2020 Feb 5;11(1):729. doi: 10.1038/s41467-020-14367-0. Nat Commun. 2020. PMID: 32024854 Free PMC article.
The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer.
Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Gram IT, Kristensen VN, Børresen-Dale AL, Lillehaug JR, Lønning PE. Staalesen V, et al. Among authors: knappskog s. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6000-4. doi: 10.1158/1078-0432.CCR-05-2822. Clin Cancer Res. 2006. PMID: 17062672
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE. Chrisanthar R, et al. Among authors: knappskog s. PLoS One. 2011 Apr 27;6(4):e19249. doi: 10.1371/journal.pone.0019249. PLoS One. 2011. PMID: 21556366 Free PMC article. Clinical Trial.
MDM2 SNP309 and risk of cervical cancer.
Knappskog S, Lønning PE. Knappskog S, et al. Tumour Biol. 2014 Jul;35(7):6185-6. doi: 10.1007/s13277-014-1910-4. Epub 2014 Apr 17. Tumour Biol. 2014. PMID: 24740562 No abstract available.
MDM2 SNP309 and risk of endometrial cancer.
Knappskog S, Lønning PE. Knappskog S, et al. Tumour Biol. 2014 Aug;35(8):7285-6. doi: 10.1007/s13277-014-2244-y. Epub 2014 Jun 26. Tumour Biol. 2014. PMID: 24964960 No abstract available.
162 results